Citations

Clear

3057 citation(s) found for "Cd, Johnson".

Superficial Cortical Aβ Clearance and ARIA Pathology in Aducanumab‐Treated Alzheimer's Disease
Boon, Baayla D.C., Piura, Yoav , Chalk, Jessica L , Lincoln, Sarah, Rutledge, Matthew H., Reichard, R. Ross, Graff‐Radford, Jonathan, Knopman, D S, Graff‐Radford, Neill R., Murray, Melissa E., Boon, Baayla D.C. , Moloney, Christina M. , Johnson, Derek R. , Dickson, Dennis W. , Nguyen, Aivi T. , Reichard, R. Ross , Graff‐Radford, Jonathan , Knopman, David S. , Graff‐Radford, Neill R. , Murray, Melissa E.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2025 | Volume: 21 | Issue: S1 | Pages: No page available

10.1002/alz70855_105890 Get It

Abstract Background Monoclonal antibodies targeting amyloid‐β (Aβ), including aducanumab, have been tested to treat Alzheimer's disease (AD). However, limited data exist on neuropathology following treatment and the effects of amyloid‐related imaging abnormalities (ARIA). We report on such data from five aducanumab‐treated study participants with AD of whom two experienced ARIA. Methods Aducanumab‐treated study participants who came to autopsy ( n = 5) were matched to AD controls ( n = 12) based on the presence/type of autosomal dominant AD mutation, APOE genotype, age at cognitive symptom onset, and sex. We assessed cognitive measures, 18 F‐florbetapir PET centiloid, ARIA risk factors, and AD neuropathologic change. Using multiplex immunofluorescence, brain regions affected along Thal Aβ phases were stained for Aβ isoforms and phosphorylated tau, as well as for ARIA‐associated markers, including Perls’ Prussian blue to detect ferric iron, fibrinogen‐α for blood brain barrier integrity, membrane attack complex (C5b‐C9) for complement activation, and activated microglia (IBA1, CD68). Results Study participants included four males and one female, all carrying at least one APOE ε4 allele. Two participants carried a PSEN1 NM_000021.4:c.817G>A , p.Glu273Lys mutation. Cumulative aducanumab dosage ranged between 5–241 mg/kg, with death occurring 5–41 months after the last infusion. Amyloid burden on PET declined in all participants (range 15‐100 centiloids). Two participants experienced ARIA. Compared to AD controls, Aβ aa1‐8 and Aβ 42 were selectively reduced in cortical layer I of aducanumab‐treated study participants ( p <0.05) but not in the total cortex, as shown for the middle frontal cortex in Figure 1. No differences were observed in phosphorylated tau burden. Prussian blue‐stained hemosiderin was present in both treated and untreated AD cases. However, in participants with ARIA, hemosiderin accumulated in superficial cortical layers near CAA‐laden meningeal and penetrating vessels, which also exhibited extensive complement and microglial activation (Figure 2). Conclusions Aβ clearance and ARIA‐related findings were localized predominantly in superficial cortical layers, suggesting that aducanumab biodistribution is more pronounced in these regions rather than deeper cortical layers.
Performance of the Lumipulse plasma p ‐tau217 assay to assess eligibility for amyloid‐lowering therapies
Ashrafzadeh‐Kian, Susan , Cogswell, Petrice M, Graff‐Radford, Jonathan, Petersen, Ronald, Ramanan, Vijay K., Algeciras‐Schimnich, Alicia , Bornhorst, Joshua , Figdore, Daniel J. , Burkett, Brian J. , Cogswell, Petrice M. , Johnson, Derek R. , McCarter, Stuart J. , Graff‐Radford, Jonathan , Petersen, Ronald, Ramanan, Vijay K.

Mayo Clinic

Alzheimer's & Dementia | December 24, 2025 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_097514 Get It

Abstract Background Clinically available plasma p ‐tau217 assays may be utilized in the determination of eligibility for amyloid‐lowering therapies. Our institution recently introduced a plasma p ‐tau217 assay in clinical practice using a two‐cutpoint approach that optimizes the accuracy while minimizing false positive risk and categorizing ≤20% of results as intermediate. In this study, we prospectively evaluate the performance of a plasma p ‐tau217 assay for detection of amyloid pathology using these predefined cutpoints. Method Patients recruited were being considered for lecanemab therapy at a tertiary care subspecialty clinic. Plasma p ‐tau217 was measured using the clinically available Fujirebio Lumipulse p ‐tau217 assay at Mayo Clinic, and results (pg/mL) were classified as either negative (≤0.185), intermediate (0.186–0.324) or positive (≥0.325). Amyloid pathology was determined by amyloid‐PET and/or CSF p ‐tau181/Aβ42. Result Ninety‐three patients were recruited between November 2023 and December 2024. Of these, 49 underwent amyloid‐PET, 4 had CSF p ‐tau181/Aβ42 measurements, and 40 had both PET and CSF results (with 3/40 discordant cases), for use in the assessment of amyloid pathology. The three discordant cases were considered amyloid positive for purposes of plasma p ‐tau217 comparison. Overall amyloid positivity was 90%. Plasma p ‐tau217 results were positive in 83% (77/93), negative in 6% (6/93), and intermediate in 11% (10/93) of patients. An elevated p ‐tau217 predicted the presence of amyloid positivity with a diagnostic accuracy of 96% (95% CI 90% − 99%). In the intermediate range, 80% of patients were positive for amyloid pathology. In patients with a definitive p ‐tau217 result (positive or negative), the positive and negative predictive values were 97% and 83%. There were three patients with discordant results: one PET+/p‐tau217‐, one PET‐/p‐tau217+, and one CSF‐/p‐tau217+. Clinical presentation of these discordant cases was examined, and relevant findings will be discussed. Conclusion The Lumipulse plasma p ‐tau217 assay exhibited acceptable diagnostic accuracy for the determination of amyloid pathology when compared to either amyloid‐PET or CSF p ‐tau181/Aβ42. This prospective study confirms the utility a two‐cutpoint approach for interpreting plasma p ‐tau217 for the assessment of amyloid pathology eligibility for amyloid‐lowering therapies in a heterogenous clinical cohort.
Prediction of neuropathology using the FDG‐PET based patient similarity network
Zhang, Gemeng , Barnard, Leland, Botha, Hugo, Gogineni, Venkatsampath, Graff‐Radford, Jonathan, Huls, Sean J. , Stricker, John L. , Fan, Winnie Z. , Wiste, Heather J. , Machulda, Mary M., Murray, Melissa E., Reichard, R. Ross, Gunter, Jeffrey L. , Schwarz, Christopher G, Kantarci, Kejal, Whitwell, Jennifer L., Josephs, K., Knopman, David S., Boeve, Brad F, Petersen, Ronald, Jack, Clifford R., Lowe, Val J. , Jones, David T., Barnard, Leland R , Botha, Hugo , Corriveau‐Lecavalier, Nick , Graff‐Radford, Jonathan , Burkett, Brian J. , Johnson, Derek R. , Khurana, Aditya , Min, Hoon-Ki Paul , Senjem, Matthew L. , Machulda, Mary M. , Murray, Melissa E. , Dickson, Dennis W. , Nguyen, Aivi T. , Reichard, R. Ross , Schwarz, Christopher G. , Kantarci, Kejal , Whitwell, Jennifer L. , Knopman, David S. , Petersen, Ronald, Jack, Clifford R. , Jones, David T.

Mayo Clinic

Alzheimer's & Dementia | December 24, 2025 | Volume: 21 | Issue: S1 | Pages: No page available

10.1002/alz70855_103746 Get It

Abstract Background Neuropathologic evaluation is essential for diagnosing and treating dementia, but definitive diagnoses is only available after post‐mortem brain autopsy. Positron emission tomography (PET) offers a potential in vivo proxy for predicting neuropathology. This study proposes a semi‐supervised learning (SSL) model using a single FDG‐PET image to predict underlying neuropathology. Method The SSL model leverages a self‐organized graph structure based on a patient similarity network (PSN) created from 1,495 FDG‐PET images across the aging and neurodegenerative spectrum. Each patient is represented by a node, with edges indicating image similarity derived from principal component analysis features and cosine similarity weights. The PSN structure connects 20 nearest neighbors. Neuropathologic labels were available for 204 autopsied patients. The Poisson Learning Method was employed to propagate labels from these annotated nodes to unlabeled nodes, guided by the PSN structure. FDG‐PET images were collected from clinical and research participants at the Mayo Clinic and processed using an MRI‐free pipeline. Neuropathologic labels were assigned based on widely accepted diagnostic criteria. Leave‐one‐out cross‐validation (LOOCV) was used to assess model performance. Results The confusion matrix demonstrated high accuracy in predicting Alzheimer's disease, frontotemporal lobar degeneration with tau inclusions, and Lewy body disease pathology. A Sankey diagram and label distribution analysis revealed strong correlations between clinical and predicted neuropathologic labels. Conclusion This study highlights the potential of a graph‐based SSL pipeline to predict neuropathological changes using FDG‐PET imaging data, despite limited pathology labels. The findings underscore the value of SSL in bridging the gap between abundant neuroimaging data and scarce neuropathologic labels, contributing to improved dementia diagnosis and understanding.
Calibration of multi‐site raters for prospective visual read of amyloid PET scans acquired across the ADRC Consortium for Clarity in ADRD Research Through Imaging (CLARiTI)
Soleimani‐Meigooni, David, Lin, Zoe, Soppe, Carol L., Koran, Mary Ellen I. , Villemagne, Victor L., Windon, Charles , Mormino, Elizabeth C. , Johnson, Sterling C., Rabinovici, Gil D., Windon, Charles , Soleimani‐Meigooni, David N. , Blazhenets, Ganna , Joie, Renaud La , Johnson, Derek R. , McConathy, Jonathan , Nasrallah, Ilya M. , Tanner, Jeremy A. , Villemagne, Victor L. , Zeineh, Michael , Johnson, Sterling C. , Rabinovici, Gil D.

Mayo Clinic

Alzheimer's & Dementia | December 23, 2025 | Volume: 21 | Issue: S8 | Pages: No page available

10.1002/alz70862_109906 Get It

Abstract Background PET visual reads for multi‐center studies are conducted centrally by one or a few experts. In CLARiTI, a broader network of raters will perform the reads, necessitating methods to ensure their accuracy and reliability. Method All ADRC sites ( N = 37) will prospectively acquire amyloid PET scans for 800 cognitively unimpaired and 1200 cognitively impaired participants. Each site can use one of four amyloid PET tracers ([ 18 F]florbetaben, [ 18 F]florbetapir, [ 11 C]PIB, [ 18 F]NAV4694). PET scans will be visually interpreted by ten PET neuroimaging experts located across eight ADRCs, using their preferred hardware, software, and file format (DICOM, NIFTI). Calibration requires readers to perform blinded, independent visual interpretation of 180 amyloid PET scans (30 unique and 15 duplicate scans per tracer), previously read and selected by an expert (Table 1). An even mix of visually non‐elevated and elevated scans were selected, with quantitation spanning ‐26‐123 Centiloids (Figure 1), and 15% were visually borderline (similar proportion to ADNI4), with quantitation spanning 4‐48 Centiloids (mean 21). Kruskal‐Wallis H test showed no significant difference in the distribution of Centiloid values for scans in each tracer group, Χ 2 (3)=2.133, p = 0.545. Result Calibration scans were read by a second expert not serving in CLARiTI. There was 97% concordance and almost perfect agreement between readers (κ=0.932, p <0.001; Figure 2). Discordantly read scans were visually borderline elevated ( N = 2), borderline non‐elevated ( N = 1), and negative ( N = 1), with quantitation of 8‐21 Centiloids (mean 14). Intra‐rater reads were 98% concordant and had almost perfect agreement (κ=0.966, p <0.001). These findings hold promise for scaling‐up visual reads in CLARiTI, and we expect ≥80% concordance and substantial to almost perfect agreement (κ≥0.7) for inter/intra‐rater reliability. Conclusion Calibration is essential for accurate/reliable amyloid PET visual reads in large multi‐center studies with multiple raters. Through the calibration process, we will develop methods to improve the adjudication of borderline/challenging scans and formalize methods for visual reads of amyloid PET tracers that are investigational (i.e., [ 11 C]PIB, [ 18 F]NAV4694). Involving multiple raters across different sites, who use diverse hardware/software/file format combinations, will mirror the natural heterogeneity present in real‐world clinical practice. This calibration set can also serve as a standardized training tool for other studies incorporating amyloid PET visual reads.
External Validation of Joint Propagation Model‐Based Tau PET CenTauR units
Leuzy, Antoine , Raket, Lars Lau, Villemagne, Victor L., Klein, Gregory , Tonietto, Matteo, Olafson, Emily, Baker, Suzanne L. , Saad, Ziad S., Bullich, Santiago , Lopresti, Brian J. , Sanabria, Sandra , Boada, Mercè, Charil, A., Collins, Emily C., Collins, Jessica, Gunn, Roger N. , Higuchi, Makoto, Hostetler, Eric D., Hutchison, R. Matthew, Iaccarino, Leonardo, Insel, Philip S., Irizarry, Michael C., Jack, C. R., Jagust, William J., Johnson, Keith A., Johnson, Sterling C., Karten, Yashmin, Marquié, Marta, Mathotaarachchi, Sulantha , Mintun, Mark A., Huang, Q., Mao, Xiaxie, Gnörich, Johannes , Pappas, Ioannis, Petersen, Ronald, Schwarz, Christopher G, Smith, Ruben, Stephens, Andrew , Whittington, Alex , Carrillo, Maria, Pontecorvo, Michael J. , Haeberlein, Samantha Budd , Dunn, Billy , Kolb, H., Stephenson, Diane , Tatton, Nadine , Brendel, M., Xie, Fang, Hansson, Oskar H., Rial, Alexis Moscoso , Rakêt, Lars Lau , Villemagne, Victor L. , Tonietto, Mattéo , Olafson, Emily, Lutz, Olivia , Boada, Merce , Betthauser, Tobey J. , Collins, Emily C. , Higuchi, Makoto, Hutchison, R. Matthew , Iaccarino, Leonardo , Insel, Philip S. , Irizarry, Michael C. , Jack, Clifford R. , Jagust, William J. , Johnson, Keith A. , Johnson, Sterling C. , Marquié, Marta , Ossenkoppele, Rik , Pappas, Ioannis , Petersen, Ronald, Chiotis, Konstantinos , Rabinovici, Gil D. , Rosa-Neto, Pedro , Schwarz, Christopher G. , Kolb, Hartmuth C. , Brendel, Matthias , Rowe, Christopher Cleon , Hansson, Oskar , Doré, Vincent

Mayo Clinic

Alzheimer's & Dementia | December 23, 2025 | Volume: 21 | Issue: S8 | Pages: No page available

10.1002/alz70862_109722 Get It

Abstract Background The Joint Propagation Model (JPM)‐based CenTauR scale was recently introduced to harmonize tau‐PET quantification across different radiotracers. This study examined how CenTauR harmonization enhances the comparability of tau‐PET quantification across matched cohorts using different tracers. The evaluation focused on three key aspects: (1) comparing tau‐PET positivity rates as defined by CenTauR, (2) evaluating its diagnostic accuracy for symptomatic AD, and (3) analyzing longitudinal changes in tau‐PET rates over time. Method The JPM, developed by the CPAD‐led Tau PET Harmonization Working Group (Leuzy et al., Alzheimers Dement. 2024; Figure 1A), models relationships between anchor point subjects and head‐to‐head tau‐PET SUVR data onto the CenTauR scale, providing conversion equations for multiple tracers. JPM equations were applied to [¹⁸F]flortaucipir SUVR (Meta‐temporal ROI) data from 561 cognitively impaired participants in the ADNI and OASIS‐3 studies. Using ROC analysis, we determined the CenTauR cut‐off for positivity (T+) that maximized the Youden index for discriminating between FDA‐approved positive/negative visual reads. Three separate cohorts, scanned using [¹⁸F]flortaucipir (ADNI), [¹⁸F]MK‐6240 (CPAS), and [¹⁸F]RO‐948 (BioFINDER‐2), were matched 1:1 by age, MMSE, amyloid‐β, and clinical diagnosis. CenTauR‐based metrics were compared across these cohorts. Result A cut‐off of 18 CenTauRs was found to optimally classify [ 18 F]flortaucipir PET visual reads (Figure 1B). The matching procedure identified 1089 participants (363 per cohort). The frequency of T+ using the 18 CenTauRs cut‐off for the Meta‐Temporal ROI was highly comparable across tracers across groups, except for the Aβ‐positive cognitively unimpaired group, where variability was more pronounced due to a smaller sample size (Figure 2A). Similarly, tau‐PET discriminative accuracy for symptomatic AD vs controls remained similar across [ 18 F]flortaucipir and [ 18 F]MK‐6240 (Figure 2B). In a separate sample of 212 matched participants from ADNI ([¹⁸F]flortaucipir) and AIBL ([¹⁸F]MK‐6240) with baseline and 1‐year follow‐up tau‐PET scans, 1‐year change in CenTauRs was comparable (Figure 2C). An exploratory voxelwise transformation, utilizing the Meta‐Temporal conversion equation in a representative case scanned with both [¹⁸F]flortaucipir and [¹⁸F]MK‐6240, demonstrates the potential for voxelwise CenTauR harmonization (Figure 3). Conclusion These analyses suggest that CenTauR harmonization increases the comparability of tau‐PET data acquired with different tracers. Additional validation analyses with larger cohorts including other radiotracers ([¹⁸F]PI‐2620) are underway.
FP7.4 Corticosteroid Induced Avascular Necrosis of the Femoral Head: Mid-Term Outcomes of Core Decompression with Bone Marrow Aspirate Concentrate Injection in Adolescents and Young Adults
Johnson, Quinn J. , Varas, Emil, Grigoriou, Emmanouil, Selemon, Nicolas A. , Varas‐Rodríguez, Emil , Sierra, Rafael J. , Grigoriou, Emmanouil

Mayo Clinic

Journal of Hip Preservation Surgery | December 22, 2025 | Volume: 12 | Issue: Supplement_2 | Pages: ii12-ii12

10.1093/jhps/hnaf069.036 Get It

Abstract Osteonecrosis (ON) of the femoral head is a significant complication following chronic corticosteroid treatment, especially in adolescents and young adults. While studies in the adult population suggest that early core decompression augmented with bone marrow aspirate concentrate injection (BMAC) may reduce progression, evidence in younger patients remains scarce. This study evaluates survivorship free from femoral head collapse and conversion to total hip arthroplasty following core decompression with BMAC in patients under 25 years old with corticosteroid-induced femoral head ON. A retrospective review was conducted of 13 patients (24 hips) who underwent hip core decompression with BMAC for corticosteroid-induced femoral head ON. Variables analyzed included sex, body-mass index, age at index surgery, continued corticosteroid use, concomitant labral tear, Kerboul angle/grade, and Steinberg classification of osteonecrosis. These variables were assessed for their association with survivorship free of THA, conversion to THA, and patient reported outcomes (PROs) (modified Harris Hip Score [mHHS] and Hip Disability and Osteoarthritis Outcome Score [HOOS-12]). The mean follow-up duration was 10 ± 5.4 years. At the final follow-up, 11 hips (45.8%) required reoperation, including 10 total hip arthroplasties and one femoral head resurfacing. Progression to radiographic femoral head collapse occurred in 9 hips (37.5%), resulting in a collapse-free survival rate of 62.5%. The mean survival time until reoperation was 8.34 years. Continued corticosteroid use (p=0.033), Steinberg stage &gt;2 (p=0.044), male sex (p=0.045), and high BMI (p=0.002) were associated with increased risk for reoperation. On multivariate analysis, ongoing corticosteroid use (OR=6.4, p=0.01) and Steinberg stage &gt;2 (OR=4.3, p=0.04) were predictors of reoperation. Patient-reported outcomes at final follow-up included a mean mHHS of 77.5 and a HOOS-12 score of 80%. Core decompression with BMAC for corticosteroid induced femoral head ON in adolescents and young adults resulted in collapse-free survival rate of 62.5% at average 10 years follow up with an average reoperation-free survival of 8.34 years. Patients with Steinberg stage ≥2 and ongoing corticosteroid use had high rates of reoperation and conversion to total hip arthroplasty. Our data highlights that careful patient selection and shared decision-making remain critical in optimizing patient outcomes in this challenging patient population.
Cortical asymmetry in autosomal dominant Alzheimer’s disease progression
Pérez-Millan, Agnès , Falgàs, Neus , Borrego-Écija, Sergi, Antonell, Anna, Fernández-Villullas, Guadalupe, Esteller-Gauxax, Diana, Tort-Merino, Adrià, Bargalló, Núria, Balasa, Mircea, Lladó, Albert, Chrem, Patricio, Day, Gregory S. , Devenney, Emma , Huey, Edward D. , Ikeuchi, Takeshi, Jucker, Mathias, Roh, Jee Hoon , Vitali, Paolo , Ortíz, Ana Luisa Sosa, Llibre-Guerra, Jorge J, Gordon, Brian A., Sánchez-Valle, Raquel, (DIAN), The Dominantly Inherited Alzheimer Network, Daniels, Alisha , Courtney, Laura, Ziegemeier, Angela, Skrbec, Karina, Hellm, Cortaiga, Martin, Mariana , Ziegemeier, Ellen , Bartzel, Jamie, Xiong, Chengie , Xu, Xiong, Lu, Ruijin, Li, Yan , Nie, Yuzheng , Gremminger, Emily, Perrin, Richard J. , Franklin, Erin , Ibanez, Laura, Jerome, Gina, Stauber, Jennifer, Baker, Bryce, Minton, Matthew, Cruchaga, Carlos C, Goate, Alison M, Renton, Alan E, Picarello, Danielle M. , Benzinger, Tammie L S, Hornbeck, Russ C. , Chen, Allison, Chen, Charles D., Flores, Shaney, Joseph-Mathurin, Nelly, Jackson, Kelley, Keefe, Sarah , Koudelis, Deborah, Massoumzadeh, Parinaz , Nicklaus, Joyce , Pulizos, Christine, Wang, Qing, Sabaredzovic, Edita, Scott, Jalen , Simmons, Ashlee, Rizzo, Jacqueline, Vlassenko, Andrei G. , Wang, Yong, Hassenstab, Jason, Smith, Jennifer, Stout, Sarah, Marsh, Jacob, Morris, John C, Barthélemy, Nicolas R. , Xu, Jinbin , Ikonomović, Snežana, Graff-Radford, Neill R, Farlow, Martin R. , Chhatwal, Jasmeer P. , Maa, Courtney, Ishiguro, Takanobu , Ishii, Kenji, Senda, Michio, Salloway, Stephen , Bechara, Jacob A, Martins, Ralph, Fox, Nick C, Ryan, Natalie S. , Laske, Christoph , Timofejavaite, Reda, Kuder-Buletta, Elke, Graber-Sultan, Susanne, Obermueller, Ulrike, Xiong, Chengjie , Rödenbeck, Yvonne, Vӧglein, Jonathan, Méndez, Patricio Chrem, Vazquez, Silvia, Leon, Yudy Milena, Ramirez, Laura, Baena, Ana , Bocanegra, Yamile , Levey, Allan, Johnson, Erik C B, Seyfried, Nicholas T. , Ringman, John M. , Fagan, Anne M. , Mori, Hiroshi, Lopera, Francisco , Goate, Alison , Hassenstab, Jason , Borrego‐Écija, Sergi , Pérez‐Millan, Agnès , Ikeuchi, T , Vöglein, Jonathan , Roh, Jee Hoon , Vitali, Paolo , Gordon, Brian A , Bateman, Randall J , Sánchez-Valle, Raquel , Day, Gregory S , Xiong, Chengjie , Hassenstab, Jason , Borrego-Écija, Sergi , Goate, Alison M , Bosch, Beatríz , Antonell, Anna, Fernández‐Villullas, Guadalupe , Esteller, Diana , Tort‐Merino, Adrià , Balasa, Mircea , Lladó, Albert , Aguillon, David , Ikeuchi, Takeshi , Jucker, Mathias , Kasuga, Kensaku , Vöglein, Jonathan , Llibre‐Guerra, Jorge J. , Gordon, Brian A. , McDade, Eric , Bateman, Randall J. , Sánchez‐Valle, Raquel , Supnet, Charlene , Lu, Ruijin, Wang, Guoqiao , Ibanez, Laura , Cruchaga, Carlos , Fulton‐Howard, Brian , Banks, Jessica N , Flores, Shaney , Goyal, Manu S. , Hobbs, Diana A. , Joseph‐Mathurin, Nelly , McCullough, Austin , McKay, Nicole S. , Wang, Yong , Smith, Jennifer, Stout, Sarah H., Aschenbrenner, Andrew J. , Karch, Celeste M. , Marsh, Jacob A. , Holtzman, David M. , Berman, Sarah , Graff‐Radford, Neill R. , Senda, Michio , Niimi, Yoshiki , Schofield, Peter R. , Brooks, William S. , Bechara, Jacob , Cash, David M. , Laske, Christoph , Fougère, Christian la , Reischl, Gerald , Lee, Jae Hong , Allegri, Ricardo , Surace, Ezequiel , Vazquez, Silvia, Ramírez, Laura, Serna, Laura, Johnson, Erik C. B. , Masters, Colin L. , Noble, James M. , Lopera, Francisco Javier

Mayo Clinic

Brain Communications | December 18, 2025 | Volume: 8 | Issue: 1 | Pages: No page available

10.1093/braincomms/fcaf488 | PMID 41523185 Get It

Abstract The cortical asymmetry index evaluates the cortical thickness asymmetry between hemispheres. We investigated cortical asymmetry index in asymptomatic and symptomatic mutation carriers of autosomal dominant Alzheimer’s disease to explore the brain asymmetry within the Alzheimer’s disease continuum. Sixty baseline T1-weighted MRI scans were obtained from the Clinic Barcelona cohort. Baseline and longitudinal MRI data from 564 participants within the dominantly inherited Alzheimer network observational study were used as an independent, confirmatory cohort. Cerebrospinal fluid and plasma neurofilament light chain levels were included when available. Cortical thickness was calculated using Freesurfer and cortical asymmetry index was calculated via an open-source pipeline. Cross-sectional analyses examined cortical asymmetry index differences based on clinical classification and APOE ε4 status, adjusting for age, sex and estimated years from onset, while correlations were assessed with age, estimated years from onset, mini-mental state examination scores, and neurofilament light. Longitudinal cortical asymmetry index evolution was modelled using generalized additive models in the dominantly inherited Alzheimer network observational study cohort, incorporating age, sex, and the interaction between group and estimated years from onset. The cortical asymmetry index successfully distinguished asymptomatic mutation carrier and symptomatic mutation carriers from healthy controls in the Clinic Barcelona cohort and symptomatic mutation carriers from controls in dominantly inherited Alzheimer network observational study. Higher cortical asymmetry index in mutation carriers (asymptomatic mutation carrier and symptomatic mutation carriers combined) and in symptomatic mutation carriers were associated with higher plasma neurofilament light levels, a closer proximity to symptom onset, and lower mini-mental state examination in the Clinic Barcelona cohort. In the dominantly inherited Alzheimer network observational study cohort, mutation carriers exhibited increased cortical asymmetry index compared to controls and correlated with elevated neurofilament light (plasma and Cerebrospinal fluid), lower mini-mental state examination, and a closer proximity to symptom onset. APOE3/3 carriers showed greater asymmetry than other APOE genotypes and significant cortical asymmetry index differences between asymptomatic mutation carrier and symptomatic mutation carriers. Longitudinally, cortical asymmetry index increased over time significantly in symptomatic mutation carriers. These findings underscore brain asymmetry as a potential biomarker for early Alzheimer’s disease progression in autosomal dominant Alzheimer’s disease, with implications for detection and monitoring tracking disease-related neuroanatomical changes.
Reduction of Erroneous ST-segment Elevation Myocardial Infarction Diagnoses
Klassen, Aaron B. , Chesney, Julie A., Wilson, Marcia J., Eastman, Susan C., Connelly, Rebecca A., Konz, Brent A, Bartelt, Jennifer M., Ring, Michael T, Winkel, Daniel, Churchill, Jason T, Griffin, Dawn M., Brady, Brian J., Bartelt, J., Johnson, Matthew P. , Gulati, Rajiv , Bennett, Courtney , Barsness, Gregory W. , Bartelt, Jason D, Wiley, Brandon, Porter, John L. , Chesney, Julie A., Wilson, Marcia J., Eastman, Susan C., Fatema, Kaniz , Connelly, Rebecca A., Winkel, Daniel B., Griffin, Dawn M., Brady, Brian J., Bartelt, Jason D., Wiley, Brandon M.

Mayo Clinic

CIN: Computers, Informatics, Nursing | December 17, 2025 | Volume: 44 | Issue: 2 | Pages: No page available

10.1097/cin.0000000000001379 | PMID 41371987 Get It

An ST-segment elevation myocardial infarction is a life-threatening condition within the spectrum of acute coronary syndrome, with well-recognized implications for short-term and long-term health outcomes. Retrospective review of our institutional electronic health records identified patterns of inaccurate acute coronary syndrome diagnostic assignment, including the presence of erroneous ST-segment elevation myocardial infarction diagnoses in discharge records. Such erroneous diagnoses in the durable health record may increase risk to patients through inadequate risk assessment and inappropriate follow-up care. Misapplication of a shortcut in our electronic health record system for rapidly ordering emergent cases was identified as a potential cause of the quality gap. To address this issue, a nurse-led quality improvement project was developed by using the define, measure, analyze, improve, and control framework. The project intervention decreased the percentage of patients with erroneous diagnoses from 24% to 7% and marginally improved nursing staff satisfaction. Our project successfully addressed an institutional quality concern. Our goal of reducing erroneous discharge diagnoses with minimal disruption to our existing practice was achieved, positively affecting our patients. Including both nurse leaders and frontline health care workers ensured the success of our project.
Assessing the Impact of Time to Diagnosis and Treatment for Patients With Pulmonary Arterial Hypertension
DuBrock, Hilary M. , Silvert, Eli , Doddahonnaiah, Deeksha , Wagner, Tyler , Sandros, Marinella , DuBrock, Hilary M , Murugadoss, Karthik , López, David Ortiz

Mayo Clinic

Pulmonary Circulation | December 16, 2025 | Volume: 15 | Issue: 4 | Pages: No page available

10.1002/pul2.70208 | PMID 41409317 Get It

ABSTRACT Pulmonary arterial hypertension (PAH) is a progressive disease with significant morbidity and mortality. Due to nonspecific symptoms, diagnosis can be challenging and subject to substantial delays. Using data from Mayo Clinic′s electronic health records, we looked at causes of delayed diagnosis and whether earlier diagnosis means better outcomes. This retrospective cohort study included adults with PAH confirmed by right heart catheterization (RHC) between 2015 and 2019. Univariate and multivariate analyses evaluated the association of 229 clinical and laboratory features with time to PAH diagnosis and survival outcomes. Early diagnosis was defined as < 6 months and a delayed diagnosis as ≥ 22.2 months from an eligible event. Survival probability was determined using Kaplan‐Meier analysis . The study enrolled 160 patients. The most common initial PAH symptoms were dyspnea (42.5%) and fatigue (16.9%). It took a median of 7, 13, 26, and 123 days from eligible event to the first X‐ray, electrocardiogram, echocardiogram, and RHC, respectively. Factors most closely associated with delayed diagnosis were chronic obstructive pulmonary disease, normal creatinine, high systolic blood pressure, acute respiratory infection, normal iron, normal diastolic blood pressure, and being male aged 18.5 to < 25 years. Compared with delayed diagnosis patients (22.6%), more early diagnosis patients saw a pulmonologist (35.3%) before another provider. After 5 years, 73% of patients in the early diagnosis and 31% in the delayed diagnosis group were still alive. This study identified factors associated with a delayed diagnosis of PAH and found that earlier diagnosis and treatment initiation were associated with significantly improved survival.
Tablet‐based Cognitive Assessment Tool (TabCAT) in a multisite study of early‐onset Alzheimer's disease
Njamnshi, Wepnyu Yembe , Chiotis, Konstantinos , Tsoy, Elena , Blazhenets, Ganna , Maiti, Piyush , Zhang, J. , Allen, Isabel Elaine , Rocha, Salma, Shankar, Ranjani , Amuiri, Alinda, Lawson, Mawuli, Aisen, Paul , Eloyan, Ani , Hammers, Dustin B. , Kirby, Kala, Koeppe, Robert, Toga, Arthur W., Clark, David A. , Day, Gregory S. , Duara, Ranjan , Graff‐Radford, Neill R., Grant, Ian , Johnson, Erik C. B. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Riddle, Meghan , Rogalskı, Emily , Salloway, Steven, Sha, Sharon J. , Turner, Raymond Scott , Wingo, Thomas S. , Kramer, Joel H. , Touroutoglou, Alexandra , Brickhouse, Michael , Jack, Clifford R. , Taurone, Alexander, Thangarajah, Maryanne, Carrillo, Marı́a C., Apostolova, Liana G. , Possin, Katherine L. , Rabinovici, Gil D. , Joie, Renaud La , Carrillo, María C. , Zhang, Jiaxiuxiu , Dickerson, Bradford Clark , La Joie, Renaud , Jack, Clifford R , Day, Gregory S , Rabinovici, Gil D , Blazhenets, Ganna , Wingo, Thomas S , Chiotis, Konstantinos , Rocha, Salma, Lawson, Mawuli, Beckett, Laurel , Hammers, Dustin B , Kirby, Kala, Kukull, Walter A. , Toga, Arthur W. , Atri, Alireza , Clark, David, Duara, Ranjan , Graff‐Radford, Neill R. , Honig, Lawrence S. , Jones, David T. , Masdeu, Joseph C , Musiek, Erik , Salloway, Steve , Wolk, David A. , Womack, Kyle , Vemuri, Prashanthi , Nudelman, Kelly

Mayo Clinic

Alzheimer's & Dementia | December 15, 2025 | Volume: 21 | Issue: 12 | Pages: No page available

10.1002/alz.71012 | PMID 41395729 Get It

Abstract INTRODUCTION Brief digital cognitive measures may be a valuable and scalable alternative to traditional tests for improving early detection and disease monitoring in patients with early‐onset Alzheimer's disease (EOAD). METHODS We examined the convergent, diagnostic, and neuroanatomical validity of Tablet‐based Cognitive Assessment Tool (TabCAT) tests in the multisite Longitudinal Early‐Onset Alzheimer's Disease Study. Four hundred seventy‐five participants from 16 sites (83 cognitively unimpaired participants, 146 individuals diagnosed with mild cognitive impairment [MCI], and 246 with mild dementia) underwent TabCAT testing, including two executive/attentional tasks (Match and Flanker) and two visuospatial tasks (Line Length and Line Orientation). RESULTS TabCAT tests showed good convergent validity with traditional pen‐and‐paper tests. Match was the most accurate TabCAT test in differentiating among clinical groups (controls vs. MCI vs. dementia) and predicting amyloid positron emission tomography (PET) positivity in clinically impaired participants. TabCAT tests were associated with regional tau PET patterns. DISCUSSION TabCAT digital measures have promise for frontline identification of patients with EOAD. Highlights Four hundred seventy‐five participants from 16 US sites underwent tablet‐based cognitive assessment. Digital tests assessed executive function and visuospatial abilities. Digital tests correlated with traditional pen‐and‐paper cognitive tests. Match (test of executive function) differentiated clinical groups. Digital tests were associated with amyloid positron emission tomography (PET) status and regional tau PET patterns.